Portfolio companies delivering as planned
The investment strategy implemented over the past two years appears to be playing out as planned. Karolinska Development is now firmly focussed on disruptive technologies, with the emphasis on an active investment in mid- and late-stage opportunities. A number of value inflection points, across many of the portfolio companies, are expected over the next 12-18 months. The convertible bond remains an issue, and the equity element of the balance sheet is sub-optimal. However, our DCF-based valuation of the four primary investments alone suggests a value of SEK566m, SEK8.92 per share, with the remaining five portfolio companies representing further upside.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.